“…Whether intermittent androgen blockade will have any effect, positive or negative, on progression–free survival or overall survival can only be determined by large multicenter randomized phase III clinical trials. Those are currently being conducted by the Southwest Oncology Group (SWOG), the National Cancer Institute of Canada (NCIC), the South European Uro–Oncological Group (SEUG) and the German Cancer Society [40]and summarized in table 2. If intermittent androgen blockade proves to be equivalent to standard continuous therapy, then QOL data will be determined of whether this approach is adopted clinically.…”